People
|
Christine A. Dudzik
|
|
|
|
Christine A. Dudzik
321 North Clark St.
Suite 3400
Chicago, IL 60654
+1 312.595.2254
+1 312.595.2250 (Fax)
 Download vCard
|
Partner
Christine Dudzik is a partner in the Intellectual Property practice group at Howrey and is based in the firm’s Chicago office.
Ms. Dudzik has worked extensively in patent litigation involving a number of technical fields including recombinant DNA, protein purification, immunology, diagnostics, agricultural chemicals, pharmaceuticals, microencapsulation and electrochemical processes. She has acquired particular expertise in large-scale and multiple party litigation involving the interface between patent litigation and FDA regulatory matters, including Abbreviated New Drug Applications (ANDAs) and other Hatch-Waxman related issues. She has participated in all aspects of litigation and arbitrations including discovery, dispositive motions, depositions, Markman hearings, and bench and jury trials, as well as appeals to the Federal Circuit. In addition, Ms. Dudzik has been involved in patent licensing matters including the preparation and negotiation of numerous patent license agreements, research and development agreements confidentiality agreements, and counseling with respect to other related patent matters. She also has experience in patent prosecution primarily in the chemical and biotechnology arts and has participated in Interferences and Opposition Proceedings and Appeals in the European Patent Office. Prior to earning her law degree, Ms. Dudzik worked as a patent agent.
Representative Highlights
- Amgen Inc. v. Chugai Pharmaceuticals, Inc./Genetics Institute . (D. Mass.) 927 F.2d 1200 (Fed. Cir. 1991) One of the first major biotech patent infringement cases to go to trial involving recombinant DNA, specifically, erythropoietin (rEPO), and purifying and isolating the EPO gene, where client Amgen’s patent was upheld and G.I.’s patent was invalidated for non-enablement.
- Bristol-Myers Squibb v. Ben Venue, Inc. (D.N.J.) Represented Ben Venue in multidistrict patent infringement action under 35 USC Section 271(e)(2) (In re Research Corporation Technologies, Inc.) involving Abbreviated New Drug Application (ANDA) for chemotherapy agent where favorable Markman decision lead to finding that patent was invalid for obviousness-type double patenting.
- American Dental Assoc. Health Foundation v. Bisco, Inc. (N.D. Ill.) Represented Bisco in a patent infringement case involving photoactive dentin bonding agents where case was settled during discovery.
Read more...
Admissions
Courts & Adjudicative Bodies
- United States Patent and Trademark Office
- United States Court of Appeals for the Federal Circuit
- United States District Court for the Northern District of Illinois
Education
- Chicago-Kent College of Law (JD, 1988)
- Northern Illinois University (BS, 1976)
|
|